RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Shares Shorted: Short Interest Up 205.4% in September

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 623 shares, an increase of 205.4% from the August 31st total of 204 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 196 shares, the days-to-cover ratio is currently 3.2 days.

RCN Pareto Strategic Allocation ETF Price Performance

PRTO stock traded up $0.07 during mid-day trading on Friday, hitting $27.58. 311 shares of the stock were exchanged. The firm’s fifty day simple moving average is $27.84. RCN Pareto Strategic Allocation ETF has a 12 month low of $24.68 and a 12 month high of $28.58. The company has a market cap of $17.38 million, a PE ratio of -28.73 and a beta of 1.07.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.